JamesChung-YinYangMD

General Surgery • Bethesda, MD

Assistant Professor, Surgery, Uniformed Services Hebert SOM

Join to view full profile

Dr. Yang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yang's full profile

Already have an account?

Office
9000 Rockville Pike
Bldg 10a Crc, Rm 3-5952
Bethesda, MD 20892
Phone+1 240-760-6223

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1984 - 1986
University of California (San Diego) Medical CenterResidency, Surgery, 1978 - 1984
University of California San Diego School of MedicineClass of 1978

Certifications & Licensure

CA State Medical License 1980 - 2025

Clinical Trials

CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma Start of enrollment: 2009 Feb 17
Completed
Phase 1, Phase 2
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Start of enrollment: 2013 Oct 24
Completed
Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2014 Oct 23
Recruiting
Phase 2
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers Start of enrollment: 2017 Apr 06
Recruiting
Phase 1, Phase 2
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Start of enrollment: 2017 Sep 21
Recruiting
Phase 1, Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Start of enrollment: 2018 Sep 06
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

685 citations
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-...
James Chih-Hsin Yang, Lecia V. Sequist, Sarayut Lucien Geater, Chun-Ming Tsai, Tony Mok
The Lancet. Oncology. 2015-07-01
124 citations
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
L Paz-Ares, E-H Tan, K O'Byrne, L Zhang, V Hirsh
Annals of Oncology. 2017-02-01
1215 citations
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinical...
Masahiro Fukuoka, Yi-Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan Swan Leong
Journal of Clinical Oncology. 2011-07-20